Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients.

Del Puerto-Nevado L, Minguez P, Corton M, Solanes-Casado S, Prieto I, Mas S, Sanz AB, Gonzalez-Alonso P, Villaverde C, Portal-Nuñez S, Aguilera O, Gomez-Guerrero C, Esbrit P, Vivanco F, Gonzalez N, Ayuso C, Ortiz A, Rojo F, Egido J, Alvarez-Llamas G, Garcia-Foncillas J; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Jan 9. doi: 10.1002/1878-0261.12438. [Epub ahead of print]

2.

Targeting inflammation in diabetic nephropathy: a tale of hope.

Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S, Egido J.

Expert Opin Investig Drugs. 2018 Nov;27(11):917-930. doi: 10.1080/13543784.2018.1538352. Epub 2018 Oct 23. Review.

PMID:
30334635
3.

Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms.

Lazaro I, Lopez-Sanz L, Bernal S, Oguiza A, Recio C, Melgar A, Jimenez-Castilla L, Egido J, Madrigal-Matute J, Gomez-Guerrero C.

Front Pharmacol. 2018 Jul 31;9:819. doi: 10.3389/fphar.2018.00819. eCollection 2018.

4.

SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition.

Lopez-Sanz L, Bernal S, Recio C, Lazaro I, Oguiza A, Melgar A, Jimenez-Castilla L, Egido J, Gomez-Guerrero C.

Lab Invest. 2018 Oct;98(10):1276-1290. doi: 10.1038/s41374-018-0043-6. Epub 2018 Mar 14.

PMID:
29540859
5.

Structure-activity studies of peptidomimetics based on kinase-inhibitory region of suppressors of cytokine signaling 1.

La Manna S, Lopez-Sanz L, Leone M, Brandi P, Scognamiglio PL, Morelli G, Novellino E, Gomez-Guerrero C, Marasco D.

Biopolymers. 2017 Nov 20. doi: 10.1002/bip.23082. [Epub ahead of print]

PMID:
29154500
6.

Atrasentan for the treatment of diabetic nephropathy.

Egido J, Rojas-Rivera J, Mas S, Ruiz-Ortega M, Sanz AB, Gonzalez Parra E, Gomez-Guerrero C.

Expert Opin Investig Drugs. 2017 Jun;26(6):741-750. doi: 10.1080/13543784.2017.1325872. Review.

PMID:
28468519
7.

TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice.

Fernández-Laso V, Sastre C, Méndez-Barbero N, Egido J, Martín-Ventura JL, Gómez-Guerrero C, Blanco-Colio LM.

Sci Rep. 2017 Apr 27;7:46679. doi: 10.1038/srep46679.

8.

Colon cancer modulation by a diabetic environment: A single institutional experience.

Prieto I, Del Puerto-Nevado L, Gonzalez N, Portal-Nuñez S, Zazo S, Corton M, Minguez P, Gomez-Guerrero C, Arce JM, Sanz AB, Mas S, Aguilera O, Alvarez-Llamas G, Esbrit P, Ortiz A, Ayuso C, Egido J, Rojo F, Garcia-Foncillas J; DiabetesCancerConnect Consortium.

PLoS One. 2017 Mar 2;12(3):e0172300. doi: 10.1371/journal.pone.0172300. eCollection 2017.

9.

Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis.

Lazaro I, Oguiza A, Recio C, Lopez-Sanz L, Bernal S, Egido J, Gomez-Guerrero C.

Clin Investig Arterioscler. 2017 Mar - Apr;29(2):51-59. doi: 10.1016/j.arteri.2016.10.003. Epub 2017 Feb 7. English, Spanish.

PMID:
28188022
10.

2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.

González N, Prieto I, Del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, Fernández-Fernández B, Aguilera O, Gomez-Guerrero C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sanchez-Niño MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Alvarez-Llamas G, Egido J, García-Foncillas J, Ortiz A; DiabetesCancerConnect Consortium.

Oncotarget. 2017 Mar 14;8(11):18456-18485. doi: 10.18632/oncotarget.14472. Review.

11.

Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Recio C, Lazaro I, Oguiza A, Lopez-Sanz L, Bernal S, Blanco J, Egido J, Gomez-Guerrero C.

J Am Soc Nephrol. 2017 Feb;28(2):575-585. doi: 10.1681/ASN.2016020237. Epub 2016 Sep 8.

12.

Targeting HSP90 Ameliorates Nephropathy and Atherosclerosis Through Suppression of NF-κB and STAT Signaling Pathways in Diabetic Mice.

Lazaro I, Oguiza A, Recio C, Mallavia B, Madrigal-Matute J, Blanco J, Egido J, Martin-Ventura JL, Gomez-Guerrero C.

Diabetes. 2015 Oct;64(10):3600-13. doi: 10.2337/db14-1926. Epub 2015 Jun 26.

13.

Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.

Oguiza A, Recio C, Lazaro I, Mallavia B, Blanco J, Egido J, Gomez-Guerrero C.

Diabetologia. 2015 Jul;58(7):1656-67. doi: 10.1007/s00125-015-3596-6. Epub 2015 Apr 28.

PMID:
25982245
14.

Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice.

Recio C, Oguiza A, Mallavia B, Lazaro I, Ortiz-Muñoz G, Lopez-Franco O, Egido J, Gomez-Guerrero C.

Basic Res Cardiol. 2015 Mar;110(2):8. doi: 10.1007/s00395-014-0458-1. Epub 2015 Jan 21.

PMID:
25604439
15.

Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.

Recio C, Oguiza A, Lazaro I, Mallavia B, Egido J, Gomez-Guerrero C.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1953-60. doi: 10.1161/ATVBAHA.114.304144. Epub 2014 Jul 10.

PMID:
25012131
16.

Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J.

Nat Rev Nephrol. 2014 Jun;10(6):325-46. doi: 10.1038/nrneph.2014.74. Epub 2014 May 6. Review.

PMID:
24802062
17.

Role of chemokines in proteinuric kidney disorders.

Moreno JA, Moreno S, Rubio-Navarro A, Gómez-Guerrero C, Ortiz A, Egido J.

Expert Rev Mol Med. 2014 Feb 17;16:e3. doi: 10.1017/erm.2014.3. Review.

PMID:
24534600
18.

Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice.

Sastre C, Rubio-Navarro A, Buendía I, Gómez-Guerrero C, Blanco J, Mas S, Egido J, Blanco-Colio LM, Ortiz A, Moreno JA.

PLoS One. 2013 Dec 30;8(12):e83713. doi: 10.1371/journal.pone.0083713. eCollection 2013.

19.

Gene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice.

Mallavia B, Oguiza A, Lopez-Franco O, Recio C, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, Egido J, Gomez-Guerrero C.

PLoS One. 2013 Jun 21;8(6):e66754. doi: 10.1371/journal.pone.0066754. Print 2013.

20.

Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis.

Mallavia B, Recio C, Oguiza A, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, Lopez-Franco O, Schindler S, Depping R, Egido J, Gomez-Guerrero C.

Am J Pathol. 2013 May;182(5):1910-21. doi: 10.1016/j.ajpath.2013.01.022. Epub 2013 Apr 16. Erratum in: Am J Pathol. 2013 Jul;183(1):326.

PMID:
23597852
21.

Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice.

Fernandez-Vizarra P, Lopez-Franco O, Mallavia B, Higuera-Matas A, Lopez-Parra V, Ortiz-Muñoz G, Ambrosio E, Egido J, Almeida OF, Gomez-Guerrero C.

Brain. 2012 Sep;135(Pt 9):2826-37. doi: 10.1093/brain/aws195.

PMID:
22961553
22.

Fcγ receptor deficiency attenuates diabetic nephropathy.

Lopez-Parra V, Mallavia B, Lopez-Franco O, Ortiz-Muñoz G, Oguiza A, Recio C, Blanco J, Nimmerjahn F, Egido J, Gomez-Guerrero C.

J Am Soc Nephrol. 2012 Sep;23(9):1518-27. doi: 10.1681/ASN.2011080822. Epub 2012 Aug 2.

23.

Targeting chemokines in proteinuria-induced renal disease.

Moreno JA, Moreno S, Rubio-Navarro A, Sastre C, Blanco-Colio LM, Gómez-Guerrero C, Ortiz A, Egido J.

Expert Opin Ther Targets. 2012 Aug;16(8):833-45. doi: 10.1517/14728222.2012.703657. Review.

PMID:
22793382
24.

Renal delivery of adenovirus and antisense oligonucleotides in rats by retrograde renal vein injection.

Ortiz-Muñoz G, Mallavia B, Lopez-Franco O, Hernandez-Vargas P, Egido J, Gomez-Guerrero C.

Methods Mol Biol. 2012;886:321-9. doi: 10.1007/978-1-61779-851-1_29.

PMID:
22639274
25.

HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis.

Madrigal-Matute J, Fernandez-Garcia CE, Gomez-Guerrero C, Lopez-Franco O, Muñoz-Garcia B, Egido J, Blanco-Colio LM, Martin-Ventura JL.

Cardiovasc Res. 2012 Jul 1;95(1):116-23. doi: 10.1093/cvr/cvs158. Epub 2012 Apr 30.

PMID:
22547655
26.

Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?

Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Barat A, Martín-Cleary C, Egido J.

BMC Nephrol. 2012 Apr 25;13:21.

27.

Targeting inflammation in cardiovascular diseases. still a neglected field?

Gómez-Guerrero C, Mallavia B, Egido J.

Cardiovasc Ther. 2012 Aug;30(4):e189-97. doi: 10.1111/j.1755-5922.2011.00274.x. Epub 2011 Apr 1. Review.

PMID:
21884009
28.

Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK.

Blanco-Colio LM, Martín-Ventura JL, Carrero JJ, Yilmaz MI, Moreno JA, Gómez-Guerrero C, Ortiz A, Egido J.

Proteomics Clin Appl. 2011 Jun;5(5-6):281-8. doi: 10.1002/prca.201000102. Epub 2011 Apr 28. Review.

PMID:
21538911
29.

Animal models of cardiovascular diseases.

Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J.

J Biomed Biotechnol. 2011;2011:497841. doi: 10.1155/2011/497841. Epub 2011 Feb 16. Review.

30.

Suppressors of cytokine signaling abrogate diabetic nephropathy.

Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, Sanz A, Blanco J, Mezzano S, Ortiz A, Egido J, Gomez-Guerrero C.

J Am Soc Nephrol. 2010 May;21(5):763-72. doi: 10.1681/ASN.2009060625. Epub 2010 Feb 25.

31.

Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases.

Panzer U, Steinmetz OM, Turner JE, Meyer-Schwesinger C, von Ruffer C, Meyer TN, Zahner G, Gómez-Guerrero C, Schmid RM, Helmchen U, Moeckel GW, Wolf G, Stahl RA, Thaiss F.

Am J Physiol Renal Physiol. 2009 Aug;297(2):F429-39. doi: 10.1152/ajprenal.90435.2008. Epub 2009 May 20.

32.

Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells.

Martín-Ventura JL, Madrigal-Matute J, Muñoz-Garcia B, Blanco-Colio LM, Van Oostrom M, Zalba G, Fortuño A, Gomez-Guerrero C, Ortega L, Ortiz A, Diez J, Egido J.

Cardiovasc Res. 2009 Aug 1;83(3):586-94. doi: 10.1093/cvr/cvp141. Epub 2009 May 7.

PMID:
19423618
33.

Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation.

Rodríguez-Mañas L, El-Assar M, Vallejo S, López-Dóriga P, Solís J, Petidier R, Montes M, Nevado J, Castro M, Gómez-Guerrero C, Peiró C, Sánchez-Ferrer CF.

Aging Cell. 2009 Jun;8(3):226-38. doi: 10.1111/j.1474-9726.2009.00466.x. Epub 2009 Feb 26.

34.

Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis.

Ortiz-Muñoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, Lopez-Franco O, Muñoz-Garcia B, Fernandez-Vizarra P, Ortega L, Egido J, Gomez-Guerrero C.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):525-31. doi: 10.1161/ATVBAHA.108.173781. Epub 2009 Jan 22.

PMID:
19164812
35.

Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.

Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J.

Eur J Pharmacol. 2008 May 31;586(1-3):259-65. doi: 10.1016/j.ejphar.2008.02.042. Epub 2008 Feb 26.

PMID:
18374327
36.

Proteomics in atherothrombosis: a future perspective.

Martín-Ventura JL, Blanco-Colio LM, Tunon J, Gomez-Guerrero C, Michel JB, Meilhac O, Egido J.

Expert Rev Proteomics. 2007 Apr;4(2):249-60. Review.

PMID:
17425460
37.

Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies.

Gallego-Delgado J, Lazaro A, Osende JI, Esteban V, Barderas MG, Gomez-Guerrero C, Vega R, Vivanco F, Egido J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S159-64.

38.

Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice.

Hernández-Vargas P, Ortiz-Muñoz G, López-Franco O, Suzuki Y, Gallego-Delgado J, Sanjuán G, Lázaro A, López-Parra V, Ortega L, Egido J, Gómez-Guerrero C.

Circ Res. 2006 Nov 24;99(11):1188-96. Epub 2006 Oct 19.

PMID:
17053192
39.

Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis.

López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J, Gómez-Guerrero C.

Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1864-70. Epub 2006 Jun 1.

PMID:
16741149
40.

Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches.

Gómez-Guerrero C, Hernández-Vargas P, López-Franco O, Ortiz-Muñoz G, Egido J.

Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):341-51. Review.

PMID:
16101544
41.

Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.

Blanco S, Vaquero M, Gómez-Guerrero C, López D, Egido J, Romero R.

Am J Hypertens. 2005 Apr;18(4 Pt 1):557-65.

PMID:
15831368
42.

Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells.

Hernández-Vargas P, López-Franco O, Sanjuán G, Rupérez M, Ortiz-Muñoz G, Suzuki Y, Aguado-Roncero P, Pérez-Tejerizo G, Blanco J, Egido J, Ruiz-Ortega M, Gómez-Guerrero C.

J Am Soc Nephrol. 2005 Jun;16(6):1673-83. Epub 2005 Apr 13.

43.

Suppressors of cytokine signaling regulate Fc receptor signaling and cell activation during immune renal injury.

Gómez-Guerrero C, López-Franco O, Sanjuán G, Hernández-Vargas P, Suzuki Y, Ortiz-Muñoz G, Blanco J, Egido J.

J Immunol. 2004 Jun 1;172(11):6969-77.

44.

Angiotensin II, the immune system and renal diseases: another road for RAS?

Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, Tomino Y, Egido J.

Nephrol Dial Transplant. 2003 Aug;18(8):1423-6. Review. No abstract available.

PMID:
12897073
45.

Differential activation of NF-kappa B, AP-1, and C/EBP in endotoxin-tolerant rats: mechanisms for in vivo regulation of glomerular RANTES/CCL5 expression.

Pocock J, Gómez-Guerrero C, Harendza S, Ayoub M, Hernández-Vargas P, Zahner G, Stahl RA, Thaiss F.

J Immunol. 2003 Jun 15;170(12):6280-91.

46.

Pre-existing glomerular immune complexes induce polymorphonuclear cell recruitment through an Fc receptor-dependent respiratory burst: potential role in the perpetuation of immune nephritis.

Suzuki Y, Gómez-Guerrero C, Shirato I, López-Franco O, Gallego-Delgado J, Sanjuán G, Lázaro A, Hernández-Vargas P, Okumura K, Tomino Y, Ra C, Egido J.

J Immunol. 2003 Mar 15;170(6):3243-53.

47.

Nitric oxide production in renal cells by immune complexes: Role of kinases and nuclear factor-kappaB.

Gómez-Guerrero C, López-Franco O, Suzuki Y, Sanjuán G, Hernández-Vargas P, Blanco J, Egido J.

Kidney Int. 2002 Dec;62(6):2022-34.

48.

Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of renin-angiotensin system: the role of NF-AT pathway.

Suzuki Y, Gómez-Guerrero C, Shirato I, López-Franco O, Hernández-Vargas P, Sanjuán G, Ruiz-Ortega M, Sugaya T, Okumura K, Tomino Y, Ra C, Egido J.

J Immunol. 2002 Oct 15;169(8):4136-46.

49.

Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis.

López-Franco O, Suzuki Y, Sanjuán G, Blanco J, Hernández-Vargas P, Yo Y, Kopp J, Egido J, Gómez-Guerrero C.

Am J Pathol. 2002 Oct;161(4):1497-505.

50.

Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells.

Haberstroh U, Pocock J, Gómez-Guerrero C, Helmchen U, Hamann A, Gutierrez-Ramos JC, Stahl RA, Thaiss F.

Kidney Int. 2002 Oct;62(4):1264-76.

Supplemental Content

Loading ...
Support Center